FDA Cautions Public on Risks of Compounded Tirzepatide

The U.S. Food and Drug Administration has issued a warning concerning the safety of compounded tirzepatide, often used as an alternative to branded weight-loss drugs. The agency points to potential dangers including contamination, incorrect drug potency, and non-sterile conditions, stemming from inadequate regulatory oversight. Consumers are advised to confirm pharmacy licenses and accreditation to mitigate these risks.